对首剂过敏的患者中第二剂Moderna和辉瑞-BioNTech新冠病毒mRNA疫苗的分级接种
Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose.
作者信息
Tuong Linh-An C, Capucilli Peter, Staicu Mary, Ramsey Allison, Walsh Edward E, Shahzad Mustafa S
机构信息
Division of Allergy and Immunology, Rochester Regional Health, Rochester, New York, USA.
Pharmacy Department, Rochester General Hospital, Rochester, New York, USA.
出版信息
Open Forum Infect Dis. 2021 Oct 6;8(12):ofab507. doi: 10.1093/ofid/ofab507. eCollection 2021 Dec.
Abstract
Two mRNA coronavirus disease 2019 (COVID-19) vaccines, Moderna and Pfizer-BioNTech, require 2 doses for maximum efficacy. This case series reports the safety and immunogenicity of a graded administration of the second dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines in patients with immediate hypersensitivity reactions to the first dose.
摘要
两种2019冠状病毒病（COVID-19）信使核糖核酸（mRNA）疫苗，即莫德纳疫苗和辉瑞-生物科技公司疫苗，需要接种两剂才能达到最大效力。本病例系列报告了对第一剂有速发型超敏反应的患者中，莫德纳和辉瑞-生物科技公司COVID-19疫苗第二剂分级接种的安全性和免疫原性。
相似文献
1
Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose.对首剂过敏的患者中第二剂Moderna和辉瑞-BioNTech新冠病毒mRNA疫苗的分级接种
Open Forum Infect Dis. 2021 Oct 6;8(12):ofab507. doi: 10.1093/ofid/ofab507. eCollection 2021 Dec.
2
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
3
COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.使用两步分级方案管理与 COVID-19 疫苗相关的疑似过敏反应和第二剂接种。
Allergy Asthma Proc. 2021 Nov 1;42(6):515-521. doi: 10.2500/aap.2021.42.210075.
4
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.在报告 Janssen（强生）和 mRNA COVID-19 疫苗（辉瑞-生物科技和莫德纳）成年受种者发生不良事件后使用 COVID-19 疫苗：免疫实践咨询委员会的更新-美国，2021 年 7 月。
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4.
5
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
6
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.mRNA COVID-19 疫苗接种后出现心肌炎报告：免疫实践咨询委员会更新-美国，2021 年 6 月。
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
7
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.《对 Moderna COVID-19 疫苗的迟发性局部过敏反应：病例系列》。
JAMA Dermatol. 2021 Jun 1;157(6):716-720. doi: 10.1001/jamadermatol.2021.1214.
8
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021.COVID-19 疫苗第二剂完成情况以及已接种人群第一剂和第二剂之间的间隔 - 美国，2020 年 12 月 14 日-2021 年 2 月 14 日。
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):389-395. doi: 10.15585/mmwr.mm7011e2.
9
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.美国 2020 年 12 月 14 日至 23 日：在接种第一剂辉瑞-BioNTech COVID-19 疫苗后出现过敏反应（包括过敏反应）。
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
10
Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose.在对辉瑞 - 生物科技公司的新冠mRNA疫苗第一剂出现速发型超敏反应后，分级给药的安全性和有效性。
J Allergy Clin Immunol Glob. 2022 Aug;1(3):175-177. doi: 10.1016/j.jacig.2022.04.005. Epub 2022 Apr 30.
引用本文的文献
1
Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions.过敏反应高风险患者中抗SARS-CoV-2疫苗的脱敏方案
Vaccines (Basel). 2023 Apr 27;11(5):910. doi: 10.3390/vaccines11050910.
2
mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation.mRNA COVID-19 疫苗过敏反应：流行病学、风险因素和评估。
Curr Allergy Asthma Rep. 2023 Mar;23(3):195-200. doi: 10.1007/s11882-023-01065-2. Epub 2023 Jan 23.
3
The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.新型冠状病毒肺炎信使核糖核酸疫苗诱导的过敏反应难题。
J Allergy Clin Immunol Glob. 2023 Feb;2(1):1-13. doi: 10.1016/j.jacig.2022.10.003. Epub 2022 Dec 13.
4
Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: A systematic review and meta-analysis.COVID-19 疫苗过敏反应疫苗和疫苗赋形剂检测的诊断准确性：系统评价和荟萃分析。
Allergy. 2023 Jan;78(1):71-83. doi: 10.1111/all.15571. Epub 2022 Nov 23.
5
Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose.在对辉瑞 - 生物科技公司的新冠mRNA疫苗第一剂出现速发型超敏反应后，分级给药的安全性和有效性。
J Allergy Clin Immunol Glob. 2022 Aug;1(3):175-177. doi: 10.1016/j.jacig.2022.04.005. Epub 2022 Apr 30.
6
Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.新型冠状病毒疫苗的不良反应和安全性：最新进展和未来方向。
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2254-2266. doi: 10.1016/j.jaip.2022.04.035. Epub 2022 May 10.
7
What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later.我们从与严重急性呼吸综合征冠状病毒 2 型疫苗相关的变应原性和不良反应中学到了什么：一年后。
Ann Allergy Asthma Immunol. 2022 Jul;129(1):40-51. doi: 10.1016/j.anai.2022.03.030. Epub 2022 Apr 4.
8
Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.新型冠状病毒疫苗二次过敏反应风险：系统评价和荟萃分析。
JAMA Intern Med. 2022 Apr 1;182(4):376-385. doi: 10.1001/jamainternmed.2021.8515.
9
Allergists Can Safely Evaluate and Revaccinate Individuals With Immediate Allergic Reactions to mRNA COVID-19 Vaccines.过敏症专科医生可以安全地评估对mRNA新冠疫苗有速发型过敏反应的个体并为其再次接种疫苗。
Open Forum Infect Dis. 2021 Nov 26;9(1):ofab584. doi: 10.1093/ofid/ofab584. eCollection 2022 Jan.
本文引用的文献
1
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach.新型冠状病毒疫苗过敏反应风险及推荐评估和管理：系统评价、荟萃分析、GRADE 评估和国际共识方法。
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3546-3567. doi: 10.1016/j.jaip.2021.06.006. Epub 2021 Jun 18.
2
Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!对第一剂新型冠状病毒mRNA疫苗的过敏反应：不要放弃接种第二剂！
Allergy. 2021 Sep;76(9):2916-2920. doi: 10.1111/all.14958. Epub 2021 Jun 9.
3
COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach.有过敏反应报告的患者的COVID-19疫苗接种：最新证据与建议方法
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2135-2138. doi: 10.1016/j.jaip.2021.03.053. Epub 2021 Apr 15.
4
Experts Discuss COVID-19-Variants and Vaccine Efficacy, Immunosuppressed Patients, and More.专家探讨新冠病毒变体与疫苗效力、免疫抑制患者等问题。
JAMA. 2021 Apr 14. doi: 10.1001/jama.2021.5938.
5
Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports.首剂 Moderna COVID-19 疫苗立即发生超敏反应后接种第二剂：两例病例报告
Ann Intern Med. 2021 Aug;174(8):1177-1178. doi: 10.7326/L21-0104. Epub 2021 Apr 6.
6
Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.新冠mRNA疫苗全身性过敏反应的误诊
Ann Allergy Asthma Immunol. 2021 Jul;127(1):133-134. doi: 10.1016/j.anai.2021.03.024. Epub 2021 Mar 27.
7
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.聚乙二醇和聚山梨酯皮肤试验在评估2019冠状病毒病疫苗反应中的应用：早期报告
Ann Allergy Asthma Immunol. 2021 Jun;126(6):735-738. doi: 10.1016/j.anai.2021.03.012. Epub 2021 Mar 26.
8
Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine.用于新型冠状病毒2型信使核糖核酸疫苗皮肤试验的无刺激性浓度。
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2476-2477. doi: 10.1016/j.jaip.2021.03.022. Epub 2021 Mar 23.
9
COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI).加拿大过敏与临床免疫学会（CSACI）为过敏症专科医生/免疫学家提供的COVID-19疫苗检测与接种指南。
Allergy Asthma Clin Immunol. 2021 Mar 15;17(1):29. doi: 10.1186/s13223-021-00529-2.
10
Acute Allergic Reactions to mRNA COVID-19 Vaccines.mRNA COVID-19 疫苗的急性过敏反应。
JAMA. 2021 Apr 20;325(15):1562-1565. doi: 10.1001/jama.2021.3976.
Zotero 插件